Skip to main content
. Author manuscript; available in PMC: 2013 Nov 1.
Published in final edited form as: Neuromodulation. 2012 Jul 2;15(6):508–519. doi: 10.1111/j.1525-1403.2012.00479.x

Figure 2.

Figure 2

The concentrations of ziconotide (ng/mL) in the plasma and lumbar CSF, and the ratio of CSF: plasma levels after the bolus intravenous delivery of ziconotide (0.1 mg/kg). Results presented represent the mean and SEM of data from 5 dogs. Calculated kinetics are presented in Table 2.